XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants

Garyfallia Poulakou, Pierre-Joseph Royer, Nikolai Evgeniev, Gwénaëlle Evanno, Françoise Shneiker, Bernard Vanhove, Odile Duvaux, Stéphane Marot, Vincent Calvez
doi: https://doi.org/10.1101/2023.10.09.23296726

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Back to top
Posted October 19, 2023.
Download PDF
Data/Code
Email
XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants
Garyfallia Poulakou, Pierre-Joseph Royer, Nikolai Evgeniev, Gwénaëlle Evanno, Françoise Shneiker, Bernard Vanhove, Odile Duvaux, Stéphane Marot, Vincent Calvez
medRxiv 2023.10.09.23296726; doi: https://doi.org/10.1101/2023.10.09.23296726
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area